The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel

Thrombosis Journal

Volumn 9, Issue , 2011, Pages

  Pettersen, Alf Aage R ^a   Arnesen, Harald ^a,b   Opstad, Trine B ^a   Seljeflot, Ingebjorg ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Clopidogrel resistanceFunctional testsVerifyNow methodVASP method; Genetic polymorphisms

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; WILD TYPE;

EID: 79953124485     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-9-4     Document Type: Article

References (45)

1. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. 10.1136/bmj.324.7329.71, 64503, 11786451.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation; the CURE trial. N Engl J Med 2001, 345:494-502. 10.1056/NEJMoa010746, 11519503.
3. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533. 10.1016/S0140-6736(01)05701-4, 11520521.
4. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007, 297:159-168. 10.1001/jama.297.2.joc60179, 17148711.
5. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246-251. 10.1016/j.jacc.2004.09.067, 15653023.
6. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005, 45:1157-1164. 10.1016/j.jacc.2005.01.034, 15837243.
7. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175. 10.1161/01.CIR.0000130846.46168.03, 15184279.
8. Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, Faille D, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008, 101:1088-1093. 10.1016/j.amjcard.2007.11.065, 18394438.
9. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375. 10.1056/NEJMoa0808227, 19106083.
10. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009, 30:916-922. 10.1093/eurheartj/ehp041, 19193675.
11. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857. 10.1001/jama.2009.1232, 19706858.
12. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362. 10.1056/NEJMoa0809171, 19106084.
13. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317. 10.1016/S0140-6736(08)61845-0, 19108880.
14. Harrison P, Frelinger A, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007, 120:323-336. 10.1016/j.thromres.2006.11.012, 17239428.
15. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007, 49:1505-1516. 10.1016/j.jacc.2006.11.044, 17418288.
16. Bonello L, Bonello-Palot N, Armero S, Bonello C, Mokhtar OA, Arques S, Dignat-George F, Camoin-Jau L, Paganelli F. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res 2010, 125:e167-70. 10.1016/j.thromres.2009.10.014, 19914687.
17. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3:85-92. 10.1111/j.1538-7836.2004.01063.x, 15634270.
18. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006, 48:2186-2191. 10.1016/j.jacc.2005.12.084, 17161243.
19. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005, 111:1153-1159. 10.1161/01.CIR.0000157138.02645.11, 15738352.
20. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004, 38:353-356. 10.1080/14017430410024324, 15804802.
21. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999, 82:1145-1152.
22. Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. Platelets 2010, 21:94-100. 10.3109/09537100903437206, 20148735.
23. Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, van 't Hof AW, Ruven HJ, Hackeng CM, Klungel OH, de Boer A, Deneer VH. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010, 31:3046-3053. 10.1093/eurheartj/ehq321, 20833683.
24. Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, Kim JS, Shin ES, Chang CW, Lee JE, Jang Y. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009, 104:46-51. 10.1016/j.amjcard.2009.02.045, 19576320.
25. Bonello L, Palot-Bonello N, Armero S, Camoin-Jau L, Paganelli F. Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism. Int J Cardiol 2010, 145(1):165-166. 10.1016/j.ijcard.2009.07.033, 19712984.
26. Bonello L, Armero S, Ait Mokhtar O, Mancini J, Aldebert P, Saut N, Bonello N, Barragan P, Arques S, Giacomoni MP, Bonello-Burignat C, Bartholomei MN, Dignat-George F, Camoin-Jau L, Paganelli F. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010, 56:1630-1636. 10.1016/j.jacc.2010.07.004, 20708365.
27. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010, 121:512-518. 10.1161/CIRCULATIONAHA.109.885194, 20083681.
28. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011, 9:185-191. 10.1111/j.1538-7836.2010.04115.x, 20955349.
29. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008, 84:236-242. 10.1038/clpt.2008.20, 18323861.
30. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007, 5:1839-1847. 10.1111/j.1538-7836.2007.02656.x, 17723123.
31. Huber K. Genetic variability in response to clopidogrel therapy: clinical implications. Eur Heart J 2010, 31:2974-2976. 10.1093/eurheartj/ehq329, 20846994.
32. Storey RF. Clopidogrel in acute coronary syndrome: to genotype or not?. Lancet 2009, 373:276-278. 10.1016/S0140-6736(08)61846-2, 19108882.
33. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS, Winters KJ. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008, 28:1483-1494. 10.1592/phco.28.12.1483, 19025429.
34. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-260. 10.1016/j.jacc.2007.06.064, 18206732.
35. Hwang SJ, Jeong YH, Kim IS, Park KS, Kang MK, Koh JS, Park JR, Park Y, Koh EH, Kwak CH, Hwang JY, Kim S. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010, 3:450-459. 10.1161/CIRCINTERVENTIONS.110.949859, 20823393.
36. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004, 109:166-171. 10.1161/01.CIR.0000112378.09325.F9, 14707025.
37. Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180:699-700. 10.1503/cmaj.090251, 2659824, 19332744.
38. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008, 52:1557-1563. 10.1016/j.jacc.2008.07.055, 19007592.
39. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157:148.e1-148.e5.
40. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010, 96:186-189. 10.1136/hrt.2009.171488, 19687016.
41. Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P, Clopton P, Zafar N, Bromberg-Marin G, Keramati S, Mahmud E. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008, 52:1052-1059. 10.1016/j.jacc.2008.05.054, 18848137.
42. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramirez C, Sabate M, Fernandez C, Hernandez-Antolin R, Escaned J, Alfonso F, Macaya C. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 2004, 16:169-174.
43. Kelly RV, Hsu A, Topol E, Steinhubl S. The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. J Invasive Cardiol 2006, 18:115-119.
44. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res 2009, 124:588-591. 10.1016/j.thromres.2009.06.012, 19631365.
45. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009, 53:1273-1278. 10.1016/j.jacc.2008.12.044, 2675920, 19358940.